Fritextsökning
Innehållstyper
-
Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”
With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.
-
We are expanding our English-language coverage
Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand...
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Mak...
-
The Future of Metrology is Coming to Your Region
Join our event series.
-
ZEISS Quality Innovations Worldwide
All events now in one video.
-
Omvärldsläget präglade life science-möte i Lund
Omvärlden avspeglades i programmet under branschkongressen The Future of Swedish & Danish Life Science. Under dagen avhandlades också finansiering, nya innovati...
-
Explore 3D Testing of Deformation and Motions
Powerful measurement capabilities with the new ZEISS ARAMIS 1.
-
How Microscopy Can Help Families Grow
Advanced microscopy solutions can help bypass challenges and natural barriers of conception.
-
Swedish drug development projects in Phase III – studies to keep an eye on
Developing new medicines is, as we know, a lengthy and uncertain process, and only a fraction of all projects ever reach late clinical phase. But it does happen...
-
Cinclus welcomes FDA announcement on single‑study requirement
Swedish Cinclus Pharma welcomes the signals from the United States that a single pivotal study, rather than two, may be sufficient when applying for market approval.
-
Atrogi on its challenger to GLP-1: “Now we are stepping forward”
A new approach to treating type 2 diabetes and obesity is taking shape in a laboratory just a stone’s throw from the Karolinska Institute. At Atrogi, researcher...
-
Webinar: Fast and Gentle Imaging of Developing Human Spinal Cord Organoids with ZEISS Lattice Lights
Imaging of complex in-vitro models.
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
Why Data and AI Skills Are Becoming Critical in Life Science Teams
Life Science organizations are investing heavily in data platforms, digital tools and AI driven solutions. From production and quality to clinical development a...
-
Lost in the recruitment process? How hiring really works today
As recruitment becomes increasingly automated, candidates are expected to adapt to both human and algorithmic decision-making. Career coach Tina Persson outline...
-
Dying man saved by artificial lung system
An external artificial lung system kept a critically ill man alive for two days until he could undergo a lung transplant. In the longer term, researchers hope t...
-
Fourteen US-based top researchers recruited to Sweden
Sweden has set its sights on America’s top scholars – and it seems to work. By the end of 2025, fourteen leading U.S.-based researchers had already been won ove...
-
100 years of Festo
The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...
-
Positive outcome in phase III for Sanofi’s eczema treatment
The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applicati...
-
Study: Autism as common in girls as in boys
Autism may be just as common in girls as in boys, but girls are diagnosed significantly later and less often during childhood, according to a large Swedish registry study.
-
Multiplex Immunofluorescence
New protocol for efficient generation of seven-color, whole slide imaging with ZEISS Axioscan.
-
Unlocking Predictive Insights for Drug Discovery and Development
3D tissue models webinar series.
-
Gene therapies on clinical hold after tumour found in five‑year‑old
The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio,...
-
Bioarctic faller på börsen efter rapport om alzheimerläkemedel
Forskningsbolaget Bioarctic föll på torsdagsförmiddagen med drygt åtta procent på börsen sedan en rapport konstaterat att de nya alzheimerläkemedlen från ett pa...
BREAKING